A cyclopyrrolone is a sedative-hypnotic compound built on a pyrrolone-based heterocyclic scaffold that produces sedation, anxiolysis, and reduced time to sleep onset through positive allosteric modulation of the GABAA receptor at or near the benzodiazepine recognition site.[1] The class is defined by this shared chemical scaffold — a pyrrolone ring system fused to additional aromatic rings — and is a tight grouping rather than a broad functional one.
Membership is chemically narrow: zopiclone, the racemic founding member, and eszopiclone, its isolated pharmacologically active S-enantiomer. The two are stereochemically related rather than independently developed — eszopiclone is the active half of zopiclone refined into its own product — and both converge on the same sedative-hypnotic effect through the same GABAA allosteric site.
Cyclopyrrolones are used clinically for the short-term management of insomnia, where they reduce sleep latency and improve sleep maintenance.[2] At therapeutic exposures the effect is sedation, anxiolysis, and a characteristic bitter metallic taste; as exposure rises the same GABAA activity deepens into psychomotor impairment, anterograde amnesia, and — at the high end or in combination with other CNS depressants — respiratory depression.
Pharmacology
Both members of the class converge on positive allosteric modulation of GABAA receptors at or near the classic benzodiazepine recognition site.[1] Binding increases the frequency of chloride channel opening, hyperpolarizes the postsynaptic neuron, and raises net CNS inhibition — the same shared endpoint as benzodiazepines and other GABAergic depressants.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Pyrrolone-scaffold GABAA modulation, broad α-subunit profile | zopiclone | Binds at or near the benzodiazepine site with low α-subunit selectivity, potentiating GABA across α1-, α2-, α3-, and α5-containing receptors |
| Pyrrolone-scaffold GABAA modulation, selective α profile | eszopiclone | Higher in vitro potency at α5-, α2-, and α3-containing receptors with lower potency at α1; modulates γ3-containing receptors with reduced efficacy but preserved potency relative to γ2[3] |
The binding domain has been mapped to a region closely related to — but distinguishable from — the canonical benzodiazepine site, and the GABAA-site antagonist flumazenil displaces cyclopyrrolones and reverses their sedation.
The mechanistic detail matters less for safety than the shared endpoint: respiratory drive is brainstem-mediated and dose-dependently suppressed through GABAA enhancement, and that effect is additive with any other depressant acting on the same axis.
Substances
The two members are best understood as one active compound in two formulations:
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Zopiclone | Cyclopyrrolone (racemate) | The founding member of the class; a 50:50 mixture of R- and S-enantiomers in which essentially all GABAA activity resides in the S-isomer. Approved across Europe and Asia for short-term insomnia treatment. |
| Eszopiclone | Cyclopyrrolone (S-enantiomer) | The isolated active S-enantiomer of zopiclone, with comparatively higher affinity at α5-, α2-, and α3-containing receptors than at α1. US-approved for insomnia, with long-duration trials showing no consistent tolerance over a year of treatment.[2] |
The two formulations differ in regulatory geography and in receptor-subunit profile, but for a person taking either the class produces a single sedative-hypnotic experience — and adds to the same depressant load when combined with other GABAergic agents.
Subjective Effects
Across the class the subjective trajectory tracks a single axis — deepening GABAA-mediated CNS inhibition — as exposure rises.[1]
| Exposure | Characteristic effects |
|---|---|
| Low | Drowsiness, reduced time to sleep onset, mild anxiolysis, and the characteristic bitter metallic taste of the cyclopyrrolone scaffold |
| Moderate–high | Deepening sedation, psychomotor incoordination, cognitive impairment, anterograde amnesia, and residual next-morning impairment (the "hangover" effect) |
| High | Profound sedation, ataxia, hypotonia, hypotension, and respiratory depression progressing toward coma |
Because the same GABAA axis drives both the hypnotic and the dangerous effects, the margin between heavy sedation and life-threatening respiratory depression narrows as exposure rises — and narrows further when any other depressant is present.
Safety
Risk profile
The defining acute danger of the class is dose-dependent CNS and respiratory depression, sharply amplified when cyclopyrrolones are combined with any other CNS depressant. Concomitant use of zopiclone or eszopiclone with prescription opioids has been associated with a substantially elevated risk of overdose events at a magnitude comparable to benzodiazepine–opioid co-prescribing.[4]
Beyond combination risk, cyclopyrrolones produce next-day psychomotor and cognitive impairment that affects driving and other complex tasks. Pharmacovigilance data have flagged parasomnias — including sleepwalking, sleep-driving, and sleep-eating — as a characteristic class-level safety signal distinct from the benzodiazepine profile.[5] Combination with alcohol, opioids, benzodiazepines, barbiturates, or sedating antihistamines should be avoided.
Like benzodiazepines, cyclopyrrolones are reversed by flumazenil at the GABAA site — though flumazenil itself can precipitate seizures in physically dependent individuals and is not a routine antidote.
Tolerance & dependence
In controlled clinical trials of up to a year, sustained eszopiclone treatment did not produce consistent tolerance,[2] and early reviews characterized dependence and abuse as comparatively rare relative to widespread use.[6] Real-world long-term data are more mixed.
Pharmacovigilance signals from the European adverse-drug-reaction database place zopiclone's dependence signal at rates comparable to zolpidem and over-represent it in overdose-related reports relative to other Z-drugs,[7] and case reports document severe physical dependence emerging after years of escalating use.[8]
Cross-tolerance with benzodiazepines is well-established and reflects the shared GABAA mechanism. It also has a clinical application: a long-acting benzodiazepine can be substituted in to manage withdrawal from cyclopyrrolones, and zopiclone itself has been used as a transitional agent when tapering patients off benzodiazepines.[9]
Abrupt cessation after sustained heavy or long-term use can precipitate a withdrawal syndrome that, at the severe end, includes seizures and hallucinations — consistent with the shared GABAA mechanism that makes alcohol and benzodiazepine withdrawal dangerous. People physically dependent on a cyclopyrrolone should not stop abruptly without clinical guidance; a gradual taper, sometimes via substitution onto a long-acting benzodiazepine, is the established approach.
Recovery
Recovery from cyclopyrrolone dependence follows the same broad pathway as recovery from other GABAA hypnotic dependence. Medically supervised gradual dose tapering is the cornerstone, and cognitive-behavioral therapy for insomnia (CBT-I) is an evidence-based adjunct that addresses the underlying sleep problem that often drives continued use. If you or someone you know has been taking zopiclone or eszopiclone regularly for an extended period, a clinician or a withdrawal-management service can structure a safe taper.Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]^abcSanger, D.J. (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents — CNS Drugs doi:10.2165/00023210-200418001-00004
- [2]^abcHair, P.I. and McCormack, P.L. and Curran, M.P. (2008) Eszopiclone: a review of its use in the treatment of insomnia — Drugs doi:10.2165/00003495-200868100-00005
- [3]^Richter, G. and Liao, V.W.Y. and Ahring, P.K. and Chebib, M. (2020) The Z-Drugs Zolpidem, Zaleplon, and Eszopiclone Have Varying Actions on Human GABAA Receptors Containing γ1, γ2, and γ3 Subunits — Frontiers in Neuroscience doi:10.3389/fnins.2020.599812
- [4]^Szmulewicz, A. and Bateman, B.T. and Levin, R. and Huybrechts, K.F. (2021) The Risk of Overdose With Concomitant Use of Z-Drugs and Prescription Opioids: A Population-Based Cohort Study — American Journal of Psychiatry doi:10.1176/appi.ajp.2020.20071038
- [5]^Toyoshima, M. and Noguchi, Y. and Otsubo, M. and Tachi, T. and Teramachi, H. (2021) Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system — International Journal of Medical Sciences doi:10.7150/ijms.51658
- [6]^Lader, M. (1997) Zopiclone: is there any dependence and abuse potential? — Journal of Neurology doi:10.1007/bf03160567